Explore more publications!
Bay State Times
Got News to Share?

Bay State Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bay State Times.

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

Press releases published on January 30, 2026

JG Autographs, Inc.'s Part II of Collecting Camelot: The Kennedy Legacy Auction is up and online now, ends February 24
Jan. 30, 2026

JG Autographs, Inc.'s Part II of Collecting Camelot: The Kennedy Legacy Auction is up and online now, ends February 24

Indeterminate EIN Presswire
Houzeo Releases the Best Places to Live in Massachusetts in 2026 with Data-Driven Insights
Jan. 30, 2026

Houzeo Releases the Best Places to Live in Massachusetts in 2026 with Data-Driven Insights

Indeterminate EIN Presswire
Crescent Biopharma Announces Grants of Inducement Awards
Jan. 30, 2026

Crescent Biopharma Announces Grants of Inducement Awards

Indeterminate GlobeNewswire
Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application
Jan. 30, 2026

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Indeterminate GlobeNewswire
Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses
Jan. 30, 2026

Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses

Indeterminate GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Jan. 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Indeterminate GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Jan. 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Indeterminate GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
Jan. 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Indeterminate GlobeNewswire
Standard BioTools Completes Sale of SomaLogic to Illumina
Jan. 30, 2026

Standard BioTools Completes Sale of SomaLogic to Illumina

Indeterminate GlobeNewswire
Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
Jan. 30, 2026

Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030

Indeterminate GlobeNewswire
EF launches search for strategic partner in bid to become world’s best cycling team
Jan. 30, 2026

EF launches search for strategic partner in bid to become world’s best cycling team

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions